Boston, MA 03\/21\/2014 (wallstreetpr) – The story begins with Aastrom Biosciences Inc (NASDAQ:ASTM)<\/b> having gained significantly in the previous session, just as it has become normal of it in recent times. Shares rose 25.19 percent to $4.97. Although the current market price of the stock is still a far cry from its one-year high of $24.40, it is encouraging to note that a lot of positive things have been happening around the stock and it could just be a matter of time before a complete turnaround is achieved. But talk is cheap, so they say, that is why apart from the rhetoric, it is important to plunge into the facts and figures to reveal Aastrom for what it is currently and what it is shaping up to be in the future.<\/p>\n
Stock trend implies bottom is almost achieved<\/b><\/p>\n
The stock price of Aastrom Biosciences Inc (NASDAQ:ASTM) is down 96 percent over the last three year. This suggests that the current price might be the bottom from which things are expected to rise to greater heights. If that is so, establishing a long-position at this point will be a beautiful move.<\/p>\n
Encouraging financial results<\/b><\/p>\n
As a matter of fact, Aastrom Biosciences Inc (NASDAQ:ASTM) did not turn up with compelling results in its latest reporting. Particularly revenue was not meaningful as one would desire, but it was encouraging to see that losses were in-line with expectations. It came out strongly that the company is doing a great job in lowering its expenses and reducing cash burn. This is a practice that if continued has the potential of shoring up the company\u2019s balance sheet and creating adequate cash hoard for future operations without looking to debts and stock offering.<\/p>\n
Reason to believe<\/b><\/p>\n
Looking at the manner in which the management is handling expenses and the cash endowment in the company, as well as many other attractive prospects ahead, it is easy to believe that the stock still has a lot of room to go up, and most of all, reward long-term investment once ongoing studies are completed successfully and the products are launched into the market.<\/p>\n","protected":false},"excerpt":{"rendered":"
Boston, MA 03\/21\/2014 (wallstreetpr) – The story begins with Aastrom Biosciences Inc (NASDAQ:ASTM) having gained significantly in the previous session, just as it has become […]<\/p>\n","protected":false},"author":15,"featured_media":17718,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[5352,5353],"stock_ticker":[],"class_list":["post-17712","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-aastrom-biosciences-inc-nasdaqastm","tag-nasdaqastm","entry"],"acf":[],"yoast_head":"\n